Sign In
Buy AVDL
$21.64
+0 (+0%)
At Close: May 08, 2026
Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
08:00am, Tuesday, 13'th May 2025
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of ma
Earnings Estimates Moving Higher for Avadel (AVDL): Time to Buy?
01:20pm, Monday, 12'th May 2025
Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Believe Avadel (AVDL) Could Rally 100.21%: Here's is How to Trade
11:00am, Monday, 12'th May 2025
The mean of analysts' price targets for Avadel (AVDL) points to a 100.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 08'th May 2025
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of A
Avadel Pharmaceuticals plc (AVDL) Q1 2025 Earnings Call Transcript
12:45pm, Wednesday, 07'th May 2025
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Austin Murtagh - IR Greg Divis - CEO Tom McHugh - CFO Conference Call Participant
Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance
07:00am, Wednesday, 07'th May 2025
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients sin
Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction
12:30pm, Tuesday, 06'th May 2025
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7
08:00am, Wednesday, 30'th Apr 2025
DUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it
Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience
08:00am, Thursday, 17'th Apr 2025
-- Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate -- -- One third of patients taking immediate-release, t
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 10'th Apr 2025
DUBLIN, April 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference
01:30pm, Tuesday, 08'th Apr 2025
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th An
Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference
08:00am, Tuesday, 01'st Apr 2025
DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of
DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
08:00am, Wednesday, 05'th Mar 2025
DUBLIN, Ireland, March 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that me
Avadel Pharmaceuticals plc (AVDL) Q4 2024 Earnings Call Transcript
11:53pm, Monday, 03'rd Mar 2025
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2024 Earnings Conference Call March 3, 2025 8:30 AM ET Company Participants Austin Murtagh - Precision AQ Gregory Divis - Chief Executive Officer Thomas Mc
